Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Author:
Publisher
Elsevier BV
Subject
Cell Biology,Dermatology,Molecular Biology,Biochemistry
Reference46 articles.
1. What improves with increased missing data imputations?;Bodner;Struct Equ Modeling,2008
2. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions;Bousquet;Drug Saf,2005
3. Drug survival rates of biologic treatments in patients with psoriasis vulgaris;Brunasso;Br J Dermatol,2012
4. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives;Burden;Br J Dermatol,2012
5. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies;Carrascosa;J Eur Acad Dermatol Venereol,2014
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis;The Lancet Rheumatology;2023-12
2. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study;Pulmonary Therapy;2023-11-22
3. Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort Study;Journal of Investigative Dermatology;2023-11
4. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease;Cureus;2023-10-11
5. Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients;JEADV Clinical Practice;2023-10-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3